/ WHAT YOU WILL RECEIVE
Real photographs of your peptides, boxed, lot-labeled, and shipped in plain unmarked packaging from our partner research lab.
More batch photos and lab footage coming soon.
PEPTIDE SEQUENCE · STRUCTURE NOTE
Y-Aib-EGTFTSDYSI-Aib-LDKIAQK-Aib-AFIEYLLEGGPSSGAPPPS-NH2
Dual GIP / GLP-1 receptor agonist with C20 diacid fatty-acid modification for extended half-life.
⏱ HALF-LIFE · PHARMACOKINETIC PROFILE
Dual GIP / GLP-1 receptor agonist
~5 days
C20 fatty-diacid modification extends plasma half-life for once-weekly dosing.
GLP-1s · RESEARCH GRADE
Tirzepatide
30mg · Lyophilized Vial
Dual GIP/GLP-1 receptor agonist, next-generation metabolic research compound.
UNIT PRICE
$79 USD
≈ CA$109
Reconstitution required
This compound requires bacteriostatic water for reconstitution. Don't forget to add a 10mL vial of BAC water to your order, available in Lab Supplies.
HOW LONG WILL IT LAST YOU?
Enter your research protocol and vial quantity — see exactly how many weeks your order covers.
Each 30mg vial lasts
6 weeks
Your 30mg vial lasts
6weeks
≈ 42 days · 6.0 doses per vial
FOR RESEARCH USE ONLY
Not for human consumption. Intended for laboratory and in-vitro research applications./ RESEARCH DOSSIER
Everything we know
about Tirzepatide.
Direct from the research literature. Every section is sourced from peer-reviewed peptide studies and clearly labelled when effects come from animal or cell-line models.
/ 01 · WHAT WE KNOW
The background.
Tirzepatide is the first dual GIP and GLP-1 receptor agonist. Published research shows superior glycemic control and body-weight reduction in clinical subjects versus GLP-1 monoagonists.
/ 02 · WHAT IT DOES FOR YOU
What researchers study it for.
Investigated for glucose regulation, appetite control, and substantial body-composition changes. GIP activity additionally supports lipid metabolism pathways.
RESEARCH HIGHLIGHTS · published animal & cell-model studies
- ▸Significant body-weight reductions in research-cohort studies vs single-agonist comparators
- ▸Improved HbA1c in T2D research models
- ▸Cardiometabolic markers showed favorable shifts in long-duration trials
Sourced from peer-reviewed research literature. Effects described are from animal & cell-line models unless otherwise noted. For research use only.
/ 03 · HOW IT WORKS
Mechanism of action.
Biological pathways identified in the research literature for Tirzepatide.
GLP-1R agonism: glucose-dependent insulin release + gastric-emptying delay
GIP receptor agonism: insulinotropic + adipocyte-signaling effects
Combined activity reduces postprandial glucose excursions and food intake in research models
Activates intracellular cAMP-PKA signaling in pancreatic β-cells
/ 04 · OVERVIEW & CLASSIFICATION
Classification.
Dual GIP/GLP-1 receptor agonist, first-in-class incretin co-agonist for metabolic research.
TYPE
Dual-agonist peptide (39 residues)
DERIVATION
Synthetic, recombinant or solid-phase synthesis with C20 fatty-diacid conjugation.
STRUCTURE
Modified GIP backbone with GLP-1 receptor activity; albumin-binding side chain extends half-life to ~5 days.
/ 05 · PHARMACOLOGICAL PROFILE
Pharmacology.
HALF-LIFE
~5 days
ABSORPTION
Subcutaneous; near-complete bioavailability
DISTRIBUTION
Albumin-bound; restricted CNS distribution
/ 06 · DOSAGE & RECONSTITUTION
Research dosing protocols.
/ 07 · PAIRS WELL WITH
Researched stacks.
Compounds explored alongside Tirzepatide in the published literature.
Retatrutide
Researchers comparing next-generation incretin compounds often run parallel Tirzepatide/Retatrutide protocols to evaluate triple-agonist (GIP/GLP-1/Glucagon) versus dual-agonist response curves.
/ 08 · SAFETY PROFILE
Safety notes.
- ▸Most common: nausea, diarrhea, decreased appetite, dose-dependent, typically improves with continued dosing
- ▸Pancreatitis signal monitored in research protocols
- ▸Contraindicated for research with MTC or MEN2 history
- ▸Caution with concomitant secretagogues, hypoglycemia risk
Research use only · not for human consumption · always consult published literature before designing any research protocol.